Business Context and Reporting Period
Company: Hemispherx Biopharma, Inc. (Note: Input metadata referenced "AIM Immunotech Inc.", but the filing text identifies the registrant as Hemispherx Biopharma, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: A biopharmaceutical company focused on immune system enhancing technologies. Key products include Ampligen® (experimental drug for Chronic Fatigue Syndrome and HIV) and Alferon N Injection® (FDA-approved for genital warts). The company is in the process of addressing FDA concerns regarding its New Drug Application (NDA) for Ampligen.
Key Financial Metrics
| Metric (in thousands) | Q1 2008 | Q1 2007 |
|---|---|---|
| Total Revenues | $208 | $255 |
| Net Loss | $(3,165) | $(5,100) |
| Loss Per Share (Basic/Diluted) | $(0.04) | $(0.07) |
| Cash and Cash Equivalents | $9,644 | $4,179 |
| Short-Term Investments | $2,989 | $3,944 |
| Total Current Assets | $14,091 | $16,599 |
| Total Current Liabilities | $2,205 | $2,187 |
| Accumulated Deficit | $(188,355) | $(185,190) |
| Net Cash Used in Operating Activities | $(2,806) | $(4,840) |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by $1.935 million (38%) compared to Q1 2007. This improvement was driven primarily by a $1.869 million (59%) reduction in Research and Development (R&D) costs and the elimination of financing costs and interest expense associated with convertible debentures that matured in June 2007.
- Revenue Decline: Total revenues decreased by $47,000 (18%) to $208,000. Sales of Alferon N Injection® dropped 21% due to competition and inventory shortages caused by product expiration dates. Ampligen® sales under the cost recovery program remained flat.
- Cost of Goods Sold: Increased slightly by 6% to $249,000, primarily due to costs associated with maintaining Alferon N Injection inventory and stability testing.
- Liquidity: Combined cash and short-term investments totaled approximately $12.6 million at March 31, 2008, a decrease of $2.8 million from the prior year-end, though management projects these funds will cover operating requirements for approximately 15 months.
Guidance, Outlook, and Risks
- Ampligen NDA Status: The company received a "Refusal to File" (RTF) letter from the FDA in December 2007 regarding its Ampligen NDA. After resolving nine of fourteen concerns in a February 2008 meeting, the company filed amendments on April 25, 2008, to address the remaining five issues. There is no assurance the FDA will accept the amended NDA or approve the drug.
- Alferon N Inventory: Sales are constrained by inventory shortages due to expiration dates. The company has petitioned the FDA for an extension of the expiration date for finished goods, but approval is not guaranteed.
- Financing Constraints: The company has a stock purchase agreement with Fusion Capital Fund II, LLC. However, purchases are suspended because the stock price is below the $1.00 threshold. Unless the price rises, no additional shares will be sold under this agreement, limiting a key source of capital.
- Risk Factors: Significant risks include the failure to obtain regulatory approval for Ampligen, inability to secure additional financing, patent challenges, and the potential for product liability claims. The company has an accumulated deficit of $188.4 million and has not been profitable since 1987.
Investor Verification Checklist
- FDA NDA Acceptance: Verify if the FDA has accepted the amended Ampligen NDA filed on April 25, 2008, for review.
- Alferon Expiration Extension: Confirm the status of the FDA petition regarding the extension of expiration dates for Alferon N Injection inventory.
- Stock Price Threshold: Monitor the common stock price to determine if it reaches the $1.00 level required to resume sales under the Fusion Capital agreement.
- Cash Runway: Assess whether the projected 15-month cash runway remains accurate given ongoing R&D and G&A expenses.
- Legal Proceedings: Review updates on litigation in South Africa and arbitration with Laboratorios del Dr. Esteve, which contributed to increased legal expenses.